I-Mab expected to post a loss of 11 cents a share - Earnings Preview

NovaBridge Biosciences

17/03/2025 24:33

I-Mab IMAB.OQ IMAB.O is expected to report resultson March 19 (estimated) for the period ending September 30 2024

​LSEG's mean analyst estimate for I-Mab is for a loss of 11 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for I-Mab is $5.50​, above​ its last closing price of $0.84. ​​​

This summary was machine generated March 17 at 00:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)